Clinical Trial Search

Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year

Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04

Primary: 11C-PBR28 Uptake as Measured by Standardized Uptake Values Normalized by a Pseudoreference Region (SUVR) — 0.9; 0.9; 1.31; 0.84 SUVR — p=0.011

Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…

Primary: Comfortable Walking Speed — .45; .60; .52; .67 meters per second — p=.405

Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci

Primary: The Berg Balance Scale (BBS) — 50; 36.1 score on a scale — p=<0.05

Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…

Primary: Response Rate — 0 percentage of participants

Primary: Core Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) — 14.3; 8.7; 9.0; 26.0 percent probability — p=0.0087

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Change in Cortical Activation — 0.054; -0.024; 0.074; -0.016 Unitless GLM beta weight (HbO) — p=0.007

Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…

Primary: Annualized Relapse Rate (ARR) — 0.02 relapses per year

Primary: Double Blind Period: Percentage of Participants With Grade 3 or 4 (Common Terminology Criteria for Adverse Events [CTCAE] v 4.0) Hematological or Liver Toxicity — 63.71…